Mankind Pharma Reports 16.5% Decline in Q3 Profit to Rs 384 Crore Despite Revenue Growth

Mankind Pharma announced a 16.5% drop in its consolidated net profit, reaching Rs 384 crore for the third quarter ending December 31, 2024. This is a decrease from the Rs 460 crore profit reported in the same period last year. However, revenue from operations increased to Rs 3,230 crore, up from Rs 2,607 crore.

Representative image

The company's domestic business saw a 15.5% year-on-year growth, reaching Rs 2,773 crore in the third quarter. The consumer healthcare segment also experienced growth, with revenue rising to Rs 193 crore compared to Rs 149 crore in the previous year's December quarter. Additionally, export revenue increased significantly to Rs 457 crore from Rs 207 crore.

Revenue Growth and Strategic Acquisitions

Vice Chairman and MD Rajeev Juneja highlighted that Mankind Pharma achieved a robust 24% year-on-year revenue growth. The company maintained a strong adjusted EBITDA margin of 27.7% in Q3FY25. This performance was driven by continued success in the chronic segment, recovery in OTC products, and the consolidation of Bharat Serums and Vaccines (BSV).

Mankind Pharma has successfully completed the acquisition of Bharat Serums and Vaccines for Rs 13,768 crore. The integration process is progressing well, focusing on key brands, enhancing productivity, and adopting best practices for sustainable growth. Juneja emphasized these efforts as crucial for long-term success.

Stock Market Performance

On Thursday, Mankind Pharma's shares closed with a gain of 4.68%, priced at Rs 2,632.70 each on the BSE. This reflects investor confidence despite the decline in net profit for the quarter.

The company's strategic moves and revenue growth indicate a positive outlook for future performance. Mankind Pharma's focus on integrating acquisitions and expanding its market presence is expected to support its long-term objectives effectively.